Mineralys Therapeutics【MLYS】銘柄情報

Mineralys Therapeutics Inc (MLYS) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

23.60

( -1.42% )

買値

17.83

売値

29.75

出来高

1,818,345

23.26 日の範囲 24.20

12.59 52 週間の範囲 47.65

時価総額

1.947B

前日終値

23.94

始値

23.93

時刻

990

23.6

(formt)

最終取引時間

財務取引量

US$ 42,941,235

VWAP

23.6156

平均取引量 (3 か月)

US$ 1,452,589

発行済株式数

82,498,101

配当利回り

PER

-11.72

1 株当たり利益 (EPS)

-2.02

歳入

純利益

-151.78M

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorena... Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

mineralystx.com

本社

Radnor, United States

設立

2026

Mineralys Therapeutics Inc is listed in the Healthcare sector of the ナスダック市場 with ticker MLYS. The last closing price for Mineralys Therapeutics was US$23.94. Over the last year, Mineralys Therapeutics shares have traded in a share price range of US$ 12.59 to US$ 47.65.

Mineralys Therapeutics currently has 82,498,101 shares in issue. The market capitalisation of Mineralys Therapeutics is US$1.95 billion. Mineralys Therapeutics has a price to earnings ratio (PE ratio) of -11.72.

全体の流れ

ブルリッシュ

ネットプレミアム

1M

Calls / Puts

100.00%

買い / 売り

16.67%

OTM / ITM

133.33%

Sweeps比率

0.00%

Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a...

Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)

RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

RADNOR, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a...

Form 8-K - Current report

Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing

– Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to...

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful...

Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference

RADNOR, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a...

Form 8-K - Current report

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-1.2	-4.83870967742	24.8	25.09	22.3	2269652	23.62859314	CS
4	-3.69	-13.5214364236	27.29	32.14	22.3	1994891	26.39805541	CS
12	0.48	2.07612456747	23.12	32.14	22.3	1447278	26.96788975	CS
26	-12.85	-35.2537722908	36.45	39.15	22.3	1363267	29.32633811	CS
52	8.2	53.2467532468	15.4	47.65	12.59	1403300	30.57510698	CS
156	8.7	58.389261745	14.9	47.65	5.85	693992	24.94795148	CS
260	2.5	11.8483412322	21.1	47.65	5.85	645103	24.68455856	CS